Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | FDPS | P14324 | 1/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 10/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 10/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 10/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 10/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 10/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 10/20 | 0.45 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.44 |
| ▸ | ABAT | P80404 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL758550 | 0.85 | PSEN1 (0.57) | ALDH1A1ALDH1A3PSEN1PSEN2APH1B | |
| SCHEMBL29940580 | 0.85 | PSEN1 (0.57) | ALDH1A1ALDH1A3PSEN1PSEN2APH1B | |
| SCHEMBL1238912 | 0.83 | KDM4E (0.54) | ALDH1A1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1238916 | 0.83 | KDM4E (0.54) | ALDH1A1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1237295 | 0.82 | ALDH1A1 (0.49) | ALDH1A1ALDH1A3TSHRFDPSPSEN1 | |
| SCHEMBL4082746 | 0.80 | ALDH1A1 (0.59) | ALDH1A1ALDH1A3TSHRFDPSTRIM24 | |
| SCHEMBL27381052 | 0.79 | ALDH1A1 (0.39) | ALDH1A1ALDH1A3TSHRFDPSTRIM24 | |
| SCHEMBL38651467 | 0.79 | ALDH1A1 (0.39) | ALDH1A1ALDH1A3TSHRFDPSTRIM24 | |
| SCHEMBL38651491 | 0.79 | ALDH1A1 (0.48) | ALDH1A1ALDH1A3PSEN1PSEN2APH1B | |
| SCHEMBL27380905 | 0.79 | MAOB (0.42) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132140-A1 | IMIDAZOLYL-AMINO-PYRAZINE-CARBONITRILS AS CHK-1 INHIBITORS | BENEVOLENTAI BIO LTD (GB) | 2026-05-14 | — | — | US | disclosed |
| WO-2024062250-A1 | IMIDAZOLYL-AMINO-PYRAZINE-CARBONITRILS AS CHK-1 INHIBITORS | BENEVOLENTAI BIO LIMITED (GB) | 2024-03-28 | — | — | WO | disclosed |
| CN-1972916-B | Cinnamide compounds | EISAI R&D MAN CO LTD | 2013-03-27 | — | — | CN | disclosed |
| CN-101723900-B | Cinnamide compounds | EISAI R&D MAN CO LTD | 2012-08-22 | — | — | CN | disclosed |
| US-20110086860-A1 | COMPOUND | KIMURA TEIJI | 2011-04-14 | — | — | US | disclosed |
| US-7880009-B2 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; (E)-N-biphenyl-3-ylmethyl-3-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)acrylamide for example; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42 | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| EP-2261218-A2 | Process for preparing phenyl-, pyridinyl- or pyrimidinyl-substituted imidazoles | Eisai R&D Management Co., Ltd. (JP) | 2010-12-15 | — | — | EP | disclosed |
| CN-101723900-A | Cinnamide compounds | EISAI R&D MAN CO LTD | 2010-06-09 | — | — | CN | disclosed |
| US-7687640-B2 | Cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-7667041-B2 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-02-23 | — | — | US | disclosed |
| US-20090281310-A1 | 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde; inhibits production of A beta 40 and A beta 42 from amyloid precursor protein ; Alzheimer's disease and Down syndrome | EISAI R&D MANAGEMENT CO., LTD. | 2009-11-12 | — | — | US | disclosed |
| US-20080070902-A1 | Cinnamide Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-03-20 | — | — | US | disclosed |
| CN-1972916-A | Cinnamide compounds | EISAI R&D MAN CO LTD (JP) | 2007-05-30 | — | — | CN | disclosed |
| EP-1757591-A1 | CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-20060004013-A1 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | EISAI CO., LTD. | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086860-A1 | COMPOUND | ARRB1, NR3C2, ADRA2C | ALDH1A1 149/4885ALDH1A3 1112/4885TSHR 2476/4885 |
| US-20260132140-A1 | IMIDAZOLYL-AMINO-PYRAZINE-CARBONITRILS AS CHK-1 INHIBITORS | CHEK1, CHEK2, BUB1 | ALDH1A1 1577/4885ALDH1A3 2435/4885TSHR 2485/4885 |
| US-20090281310-A1 | 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde; inhibits production of A beta 40 and A beta 42 from amyloid precursor protein ; Alzheimer's disease and Down syndrome | APP, PSEN1, BACE1 | ALDH1A1 451/4885ALDH1A3 1638/4885TSHR 4695/4885 |
| US-20080070902-A1 | Cinnamide Compound | C1S, CCR1, CNR1 | ALDH1A1 58/4885ALDH1A3 366/4885TSHR 3629/4885 |
| US-20060004013-A1 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | PSEN1, APP, BACE1 | ALDH1A1 1375/4885ALDH1A3 3866/4885TSHR 4527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.